ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson’s Disease
January 12, 2022
ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson’s disease ABL301 uses ABL’s Grabody-B platform technology to effectively cross the blood-brain barrier ABL to receive $75M upfront and up to $985M in potential milestone payments for exclusive […]